Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 29.447
NA - Nord America 7.498
EU - Europa 6.209
SA - Sud America 4.798
AF - Africa 610
OC - Oceania 236
Continente sconosciuto - Info sul continente non disponibili 8
Totale 48.806
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 12.582
US - Stati Uniti d'America 6.343
SG - Singapore 6.057
CN - Cina 4.539
BR - Brasile 3.398
HK - Hong Kong 1.838
IT - Italia 1.434
RU - Federazione Russa 833
TR - Turchia 690
KR - Corea 683
FR - Francia 681
MX - Messico 676
BD - Bangladesh 565
DE - Germania 559
IN - India 556
ES - Italia 551
AR - Argentina 455
GB - Regno Unito 358
ID - Indonesia 352
CA - Canada 335
JP - Giappone 328
FI - Finlandia 318
CO - Colombia 276
AU - Australia 216
EC - Ecuador 183
IQ - Iraq 180
NL - Olanda 177
PK - Pakistan 177
SA - Arabia Saudita 167
CL - Cile 156
PL - Polonia 155
AT - Austria 153
ZA - Sudafrica 144
VE - Venezuela 113
PH - Filippine 108
EG - Egitto 107
GR - Grecia 100
SE - Svezia 100
PT - Portogallo 95
MA - Marocco 88
UA - Ucraina 87
CH - Svizzera 84
CZ - Repubblica Ceca 83
PE - Perù 83
PY - Paraguay 71
UZ - Uzbekistan 69
KZ - Kazakistan 68
IL - Israele 60
TN - Tunisia 60
DZ - Algeria 59
NO - Norvegia 54
TW - Taiwan 54
MY - Malesia 49
RO - Romania 49
HU - Ungheria 45
KE - Kenya 43
AE - Emirati Arabi Uniti 40
BE - Belgio 36
MD - Moldavia 36
TH - Thailandia 36
HR - Croazia 32
BO - Bolivia 31
CR - Costa Rica 31
NP - Nepal 31
JO - Giordania 29
SK - Slovacchia (Repubblica Slovacca) 29
UY - Uruguay 29
AZ - Azerbaigian 27
DO - Repubblica Dominicana 27
IE - Irlanda 26
GT - Guatemala 24
OM - Oman 24
DK - Danimarca 23
ET - Etiopia 23
NZ - Nuova Zelanda 20
SI - Slovenia 19
AL - Albania 18
LT - Lituania 17
RS - Serbia 17
SN - Senegal 17
LB - Libano 15
PS - Palestinian Territory 15
GE - Georgia 13
SY - Repubblica araba siriana 13
JM - Giamaica 12
HN - Honduras 10
NG - Nigeria 10
AM - Armenia 9
BY - Bielorussia 9
KG - Kirghizistan 9
LK - Sri Lanka 9
LY - Libia 9
PA - Panama 9
QA - Qatar 9
AO - Angola 8
BG - Bulgaria 8
KW - Kuwait 8
XK - ???statistics.table.value.countryCode.XK??? 8
BH - Bahrain 7
EE - Estonia 7
Totale 48.683
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 4.014
Hanoi 3.211
Singapore 2.616
Hong Kong 1.774
Hefei 1.647
San Jose 1.162
Seoul 637
Ashburn 528
Chicago 525
Lauterbourg 397
Los Angeles 355
Da Nang 350
Haiphong 343
São Paulo 332
Ha Long 291
The Dalles 289
New York 283
Dallas 269
Buffalo 259
Quận Bình Thạnh 247
Biên Hòa 246
Milan 246
Helsinki 241
Istanbul 214
Hải Dương 210
Ninh Bình 198
Beijing 197
Thái Nguyên 191
Council Bluffs 189
Rome 177
Vũng Tàu 177
Can Tho 173
Melbourne 173
Moscow 166
Bắc Ninh 145
Rio de Janeiro 143
Ankara 136
Madrid 124
Jakarta 123
Bắc Giang 118
Frankfurt am Main 114
Quận Một 113
Phủ Lý 107
Quận Phú Nhuận 106
Tokyo 100
Shanghai 98
Mexico City 95
Guangzhou 94
Bogotá 91
Montreal 91
Quận Sáu 88
Thái Bình 79
Vinh 77
Santiago 76
Toronto 76
Baghdad 74
Barcelona 73
Brasília 72
Lấp Vò 72
Buenos Aires 71
Curitiba 71
Vienna 71
Quito 70
Quận Tân Phú 69
Lang Son 68
Uyen Hung 68
Medellín 67
Belo Horizonte 65
Paris 65
Riyadh 65
Điện Bàn 65
Jeddah 64
London 63
Karachi 62
Lima 62
Guadalajara 60
Hangzhou 59
Santa Clara 59
Vĩnh Tường 59
Dhaka 58
Nuremberg 58
Quận Năm 58
Tashkent 58
Quảng Ninh 55
Thu Dau Mot 55
Naples 53
Amsterdam 52
Cairo 51
Manchester 51
Porto Alegre 51
Bến Tre 50
Cologne 50
Quận Bảy 50
Bologna 49
Thành Phố Bà Rịa 49
Johannesburg 48
Athens 47
Goiânia 47
Lappeenranta 47
Bình Dương 46
Totale 27.198
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 3.818
Classification criteria for autoinflammatory recurrent fevers 2.180
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.287
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 921
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 604
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 539
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 482
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 419
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 411
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 406
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 402
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 398
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 384
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 383
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 372
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 370
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 368
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 362
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 361
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 353
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 340
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 334
Localized scleroderma in childhood is not just a skin disease 330
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 323
Criteria to define response to therapy in paediatric rheumatic diseases 320
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 264
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 255
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 249
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 248
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 243
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 242
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 235
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 228
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 227
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 216
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 213
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 211
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 210
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 208
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 208
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 207
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 205
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 205
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 204
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 203
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 198
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 198
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 196
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 194
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 190
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 180
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 178
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 177
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 175
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 171
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 171
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 169
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 169
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 168
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 166
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 164
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 162
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 162
Adalimumab in Juvenile Rheumatoid Arthritis Reply 157
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 154
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 153
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 151
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 151
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 147
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 145
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 145
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 144
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 142
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 141
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 136
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 134
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 133
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 132
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 132
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 131
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 130
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 130
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 129
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 128
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 127
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 127
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate 127
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 123
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 123
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 123
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 122
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 122
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 122
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 122
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 119
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 118
Correction: A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry [Pediatr Rheumatol., 15, (2017) (84)] DOI: 10.1186/s12969-017-0213-x 115
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis 114
JIA, Today and Tomorrow 113
Emerging therapies for juvenile arthritis: agents in early clinical trials 112
Totale 29.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.628
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202640.446 10.069 7.688 3.113 4.583 1.858 1.286 3.311 1.998 2.212 2.449 1.879 0
Totale 50.489